Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 15, Issue 1, Pages 85-93
Publisher
Informa UK Limited
Online
2014-09-18
DOI
10.1586/14737140.2015.961430
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nanoparticulation of BCG-CWS for application to bladder cancer therapy
- (2014) Takashi Nakamura et al. JOURNAL OF CONTROLLED RELEASE
- The mechanism of action of BCG therapy for bladder cancer—a current perspective
- (2014) Gil Redelman-Sidi et al. Nature Reviews Urology
- Modulating the immune response to Bacillus Calmette-Guérin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer?
- (2013) Nikhil Sapre et al. BJU INTERNATIONAL
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
- (2013) Marko Babjuk et al. EUROPEAN UROLOGY
- Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
- (2013) Maurizio Brausi et al. EUROPEAN UROLOGY
- Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro
- (2012) Karine Rech Begnini et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine
- (2012) Koji Kawai et al. CANCER SCIENCE
- Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells
- (2012) Guo-qing Ding et al. Journal of Zhejiang University-SCIENCE B
- Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice
- (2011) CHIH-WEI LIN et al. APMIS
- Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladdera
- (2011) Shouki Bazarbashi et al. BJU INTERNATIONAL
- Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein
- (2011) Yihao Deng et al. MICROBIOLOGY AND IMMUNOLOGY
- Recent advances in bacillus Calmette–Guerin immunotherapy in bladder cancer
- (2010) Anton B Alexandroff et al. Immunotherapy
- Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance
- (2010) Yonghua Wang et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- A Novel Bacillus Calmette-Guérin-based Breast Cancer Vaccine that Coexpresses Multiple Tandem Repeats of MUC1 and CD80 Breaks the Immune Tolerance and Inhibits MUC1-Positive Breast Cancer Growth
- (2009) Shifang Yuan et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro
- (2009) Wujiang Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12
- (2009) D. A. Zaharoff et al. CANCER RESEARCH
- Effective anti-tumor responses induced by recombinant bacillus Calmette–Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF
- (2009) Shifang Yuan et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer
- (2009) Per-Uno Malmström et al. EUROPEAN UROLOGY
- The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer
- (2009) Paolo Gontero et al. EUROPEAN UROLOGY
- Intravesical Mycobacterial Cell Wall-DNA Complex in the Treatment of Carcinoma In Situ of the Bladder After Standard Intravesical Therapy Has Failed
- (2009) Alvaro Morales et al. JOURNAL OF UROLOGY
- The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer
- (2009) Priscila M. Andrade et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall ofMycobacterium bovisbacillus Calmette-Guérin
- (2008) Akira Joraku et al. BJU INTERNATIONAL
- Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer
- (2008) Dinesh Ahirwar et al. CANCER GENETICS AND CYTOGENETICS
- Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model
- (2008) Daher C Chade et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story
- (2007) Harry W. Herr et al. JOURNAL OF UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started